Asia
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
TRIGR Therapeutics, based in Irvine California, signed a deal with South Korean company ABL Bio Corporation. TIRGR is licensing the global commercial rights to ABL Bio’s pipeline of antibodies to treat cancer.
Biotech manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated. Here’s everything you need to know.
Athenex is kicking off the second half of 2018 with a bang. The company secured $100 million in investments from Perceptive Advisors, is making major inroads in China with a joint venture with Chinese biotech Xiangxue Life Sciences and an in-licensing agreement from Avalon PolyTom Limited.
This week had a few disappointing clinical trials, as do most weeks, but it also had a number of significant successes. Here’s a look at some of the clinical trials that met their primary endpoints this week.
Chinese companies and investors continue to flex their financial muscles with a series of deals this week that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape.
Days after the U.S. Food and Drug Administration provided an expedited path forward for Sage Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Luye Pharma Group Ltd., announced today it is expanding its relationship with U.S. biotech firm Elpis Biopharmaceuticals Corp., to work on dual-target based therapies for cancer patients who fail to respond to current treatment.
Blueprint Medicines Corporation and privately held CStone Pharmaceuticals have entered into a partnership to develop and commercialize avapritinib, BLU-554 and BLU-667 in mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies.
PRESS RELEASES